William J. Chase - 14 Jun 2023 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role: Director
Signature: /s/James Basta, Attorney-In-Fact
Issuer symbol: NTLA
Transactions as of: 14 Jun 2023
Net transactions value: $0
Form type: 4
Filing time: 16 Jun 2023, 16:30:18 UTC
Previous filing: 18 Apr 2023
Next filing: 11 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NTLA	Common Stock	Award	$0	+1,673	+9.7%	$0.000000	18,956	14 Jun 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	NTLA	Stock Option (right to buy)	Award	$0	+2,447		$0.000000	2,447	14 Jun 2023	Common Stock	2,447	$45.20	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2	This option was granted on June 14, 2023 with respect to 2,447 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.